Prodromal manifestations of Parkinson's disease in adults with 22q11.2 microdeletion syndrome
Carlos Juri CiD, Pedro Chaná‐CuevasiD, Vasko KrameriD, Rosemarie Fritsch MiD, Claudia Ornstein, Analía Cuiza, Carlos F. HernándeziD, Katiuska Villanueva, T. Córdova, Jorge MauroiD, Adrian Ocampo, Boris Rebolledo‐JaramilloiD, Gonzalo EncinaiD, Andrea Calleja, Javiera Dinator, Juan Pablo Alcayaga, Nicolas Andres CrossleyiD, Gabriela M. RepettoiD
Abstract
22q11.2 microdeletion syndrome (22qDS) was recently identified as a risk factor for development of early-onset Parkinsons disease (PD). The classical motor manifestations of this disease are preceded by early signs and symptoms of neurodegeneration. The progression of 22qDS-associated PD is unknown. We aimed to evaluate the presence of prodromal PD in a group of adults with 22qDS using the Movement Disorders Society (MDS) Criteria for Prodromal PD. Thirty-eight persons with 22qDS and 13 age-matched controls participated in the study, and their results were compared using the Mann-Whitney U test. Persons with 22qDS had lower scores on olfaction testing (p=7.42Ex10-5), higher scores on the COMPASS 31 scale for dysautonomia (p=2.28x10-3) and on the motor evaluation using Movement Disorder Society (MDS)-sponsored revision of Unified Parkinsons Disease Rating Scale motor subscore (UPDRS-III) (p=1.84x10-4), compared with healthy controls. Home polysomnogram did not find participants with REM-sleep behavior disorder. Integrity of nigrostriatal dopaminergic system was evaluated by PET-CT imaging of presynaptic dopamine with 18F-PR04.MZ. Patients showed significantly higher specific binding ratios in the striatum, compared to controls (p=9.57x10-3 at the caudate nuclei). Two patients with 22qDS (5.2%) had decreased uptake in the posterior putamen (less than 60% of controls) and one fulfilled MDS criteria for prodromal PD. These results show that patients with 22qDS manifest some signs and symptoms of prodromal PD such as hyposmia, dysautonomia and mild movement alterations. In the majority, this was associated with elevated dopaminergic signaling, suggesting that loss of dopaminergic neurons may not be the cause. A smaller subgroup did show evidence of a decrease in nigrostriatal dopaminergic signaling, as seen in classical prodromal PD. Longitudinal studies are necessary to understand the progression to and risk of PD in persons with 22qDS.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Is Tau the Initial Pathology in Dopaminergic Nigrostriatal Degeneration? Studies in Parkinsonism and Parkinson ' Disease
Y. Chu, W. D. Hirst, … J. H. Kordower·bioRxiv·Aug 4, 2022
- The Neuropsychiatry of 22q11.2 Deletion Syndrome: An Electronic Health Records Study.
Cameron James Watson, Maria Rogdaki, … Thomas Arthur Pollak·medRxiv·Aug 4, 2026
- Atypical response inhibition and error processing in 22q11.2 Deletion Syndrome and Schizophrenia: Towards neuromarkers of disease progression and risk
Ana A. Francisco, Douwe J. Horsthuis, … Sophie Molholm·NeuroImage ClinicalPeer-reviewed·Jan 1, 2020
- Olfactory Deficits and Structural Anomalies of the Peripheral Olfactory System in 22q11.2 Deletion Syndrome
David R. Roalf, Donna M. McDonald‐McGinn, … Raquel E. Gur·bioRxiv·Oct 12, 2026
- Nonmotor symptoms associated with progressive loss of dopaminergic neurons in a mouse model of Parkinson's disease
Anna Radlicka-Borysewska, Judyta Jabłońska, … Jan M. Rodriguez Parkitna·bioRxiv·Jan 23, 2023
- Synaptic microRNA dysregulation orchestrates aberrant glutamatergic transmission in a human neuronal model of 22q11.2 deletion syndrome
Weibo Niu, Jidong Guo, … Zhexing Wen·bioRxiv·Oct 15, 2026